SCHEMBL29478779

SCHEMBL29478779

N#Cc1ccnc(CO)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.43
MBOAT4 Q96T53 1/20 0.40
CLK4 Q9HAZ1 1/20 0.39
KCNH2 Q12809 1/20 0.36
NPY5R Q15761 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
VNN1 O95497 1/20 0.35
RECQL P46063 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
ENPP2 Q13822 1/20 0.33
GRM4 Q14833 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481078 1.00 NOTUM (0.43) NOTUMMBOAT4CLK4KCNH2NPY5R
SCHEMBL3870198 0.85 CCNC (0.40) NOTUMMBOAT4CLK4KCNH2NPY5R
SCHEMBL14546705 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C
SCHEMBL18078827 0.80 MBOAT4 (0.40) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL3242600 0.80 CYP1A2 (0.44) MBOAT4CLK4KCNH2NPY5RCCNC
SCHEMBL30607265 0.80 MBOAT4 (0.40) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL19640161 0.80 HDAC8 (0.41) RECQL
SCHEMBL16532586 0.80 MBOAT4 (0.43) MBOAT4CLK4KDM4CCCNCCDK8
SCHEMBL7666624 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C
SCHEMBL17168474 0.80 MBOAT4 (0.40) MBOAT4CLK4KCNH2NPY5RKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
CN-114269340-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 NOTUM 4575/4885MBOAT4 4533/4885CLK4 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.